Literature DB >> 10739175

Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population.

H R Dhaini1, G N Levy.   

Abstract

The frequency distributions of human N-acetyltransferase 1 (NAT1*) alleles in various ethnic groups are largely unknown. This lack of information is in contrast to the many studies of ethnic differences in NAT2* alleles and phenotypes. Increasing interest in NAT1 due to its potential roles in carcinogen metabolism and cancer risk makes it desirable to know the distribution of NAT1* alleles in various populations. Using a polymerase chain reaction-restriction fragment length polymorphism genotyping assay, the frequency of NAT1* alleles in a Lebanese population was determined. Of 84 NAT1* alleles assayed, 56% were NAT1*4. Alleles NAT1*3, *10, and *14 were found at frequencies of 0.036, 0.107, and 0.238, respectively. Five additional alleles (6%) differed from previously reported alleles. Nearly 50% of the population were heterozygous for a NAT1*14 allele. The unusually high frequency of NAT1*14 alleles in Lebanese may be useful for epidemiological studies of the effects of the NAT1 polymorphism in this population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739175     DOI: 10.1097/00008571-200002000-00010

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  9 in total

1.  Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

2.  Distribution of arylamine N-acetyltransferase 2 (nat2) genotypes among Omanis.

Authors:  Musbah O M Tanira; Mehmet Simsek; Khalid Al Balushi; Khulood Al Lawatia; Hameedah Al Barawani; Riad A Bayoumi
Journal:  J Sci Res Med Sci       Date:  2003-08

Review 3.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  CYP2E1 and NQO1 genotypes and bladder cancer risk in a Lebanese population.

Authors:  Hussein A Basma; Loulou H Kobeissi; Michel E Jabbour; Mohamad A Moussa; Hassan R Dhaini
Journal:  Int J Mol Epidemiol Genet       Date:  2013-11-28

5.  Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1.

Authors:  Y Zhu; D W Hein
Journal:  Pharmacogenomics J       Date:  2007-10-02       Impact factor: 3.550

6.  Bladder Cancer Screening in Lebanese Population: There is Nothing more Unequal than the Equal Treatment of Unequal People.

Authors:  Mohammed Shahait; Muhammad Bulbul
Journal:  Bladder Cancer       Date:  2016-10-27

7.  Bladder Cancer in Lebanon: Incidence and Comparison to Regional and Western Countries.

Authors:  Najla A Lakkis; Salim M Adib; Ghassan N Hamadeh; Rana T El-Jarrah; Mona H Osman
Journal:  Cancer Control       Date:  2018 Jan-Dec       Impact factor: 3.302

8.  N-Acetyltransferase 1 (NAT1) Genotype: A Risk Factor for Urinary Bladder Cancer in a Lebanese Population.

Authors:  Ibrahim A Yassine; Loulou Kobeissi; Michel E Jabbour; Hassan R Dhaini
Journal:  J Oncol       Date:  2012-08-22       Impact factor: 4.375

9.  560G>A (rs4986782) (R187Q) Single Nucleotide Polymorphism in Arylamine N-Acetyltransferase 1 Increases Affinity for the Aromatic Amine Carcinogens 4-Aminobiphenyl and N-Hydroxy-4-Aminobiphenyl: Implications for Cancer Risk Assessment.

Authors:  Mark A Doll; David W Hein
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.